Fig. 6.

PF-06650833 inhibits type I interferon signature in vivo in humans. 300 mg of MR PF-06650833 was administered QD for 14 days in a Phase 1 MAD trial in healthy human volunteer subjects. A PAXgene whole blood tube was collected on day 0 prior to the first dose and on day 14 prior to administration of the last dose, RNA extracted, and a composite gene signature calculated as described in Methods. Plotted is the percentage change in the composite gene signature for each individual participant between the two timepoints. (Black line indicates median, box indicates 2 center quartiles, n = 11 placebo, n = 7 300 MG MR QD)